ELITE PHARMACEUTICALS INC /NV/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ELITE PHARMACEUTICALS INC /NV/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Mar 31, 2021 | $25.38M | Jun 14, 2021 |
| FY2021 | Mar 31, 2020 | $17.99M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $7.57M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $7.46M | Jun 21, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $84.04M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $56.63M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $34.16M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $32.26M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $25.38M | Jun 29, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $1.60M | Jun 14, 2018 |
| FY2018 | Dec 31, 2017 | $2.54M | Jun 14, 2018 |
| FY2018 | Sep 30, 2017 | $1.62M | Jun 14, 2018 |
| FY2018 | Jun 30, 2017 | $1.70M | Jun 14, 2018 |
| FY2018 | Mar 31, 2017 | $1.35M | Jun 14, 2018 |
| FY2018 | Dec 31, 2016 | $2.33M | Jun 14, 2018 |
| FY2018 | Sep 30, 2016 | $2.69M | Jun 14, 2018 |
| FY2018 | Jun 30, 2016 | $3.27M | Jun 14, 2018 |
| FY2018 | Mar 31, 2016 | $5.20M | Jun 14, 2018 |
| FY2018 | Dec 31, 2015 | $2.19M | Jun 14, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $40.09M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $26.36M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $16.59M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $14.80M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $11.87M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $7.98M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $2.87M | Jun 29, 2020 |
| FY2018 | Mar 31, 2018 | $1.14M | Jun 14, 2018 |
| FY2018 | Dec 31, 2017 | $1.12M | Jun 14, 2018 |
| FY2018 | Sep 30, 2017 | $1.01M | Jun 14, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($4.31M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $20.11M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $3.56M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $8.90M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $5.09M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($2.24M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($9.28M) | Jun 29, 2020 |
| FY2018 | Mar 31, 2018 | ($2.83M) | Jun 14, 2018 |
| FY2018 | Dec 31, 2017 | ($490.0K) | Jun 14, 2018 |
| FY2018 | Sep 30, 2017 | $1.82M | Jun 14, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $19.60M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $10.79M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $3.68M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $5.07M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $2.10M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($2.29M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($9.16M) | Jun 29, 2020 |
| FY2018 | Mar 31, 2018 | ($2.62M) | Jun 14, 2018 |
| FY2018 | Dec 31, 2017 | ($2.06M) | Jun 14, 2018 |
| FY2018 | Sep 30, 2017 | ($2.13M) | Jun 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $7.96M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $6.88M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $6.20M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $4.05M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $5.11M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $5.53M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $7.60M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $9.62M | Jun 21, 2019 |
| FY2018 | Mar 31, 2017 | $8.30M | Jun 14, 2018 |
| FY2018 | Mar 31, 2016 | $12.43M | Jun 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $7.46M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | ($3.24M) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $3.34M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $6.51M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $3.19M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($1.79M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($6.79M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($4.81M) | Jun 21, 2019 |
| FY2018 | Mar 31, 2017 | ($7.88M) | Jun 14, 2018 |
| FY2018 | Mar 31, 2016 | ($2.77M) | Jun 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.63M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $809.7K | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $5.74M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $498.6K | Jun 29, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $96.39M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $83.65M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $40.90M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $35.15M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $26.19M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $24.96M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $24.40M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $30.88M | Jun 21, 2019 |
| FY2018 | Mar 31, 2017 | $34.31M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $31.67M | Jun 14, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $42.87M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $26.07M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $11.94M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $9.93M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $10.04M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $14.30M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $13.01M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $12.41M | Jun 21, 2019 |
| FY2018 | Mar 31, 2017 | $8.65M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $20.51M | Jun 14, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $53.52M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $57.58M | Jun 30, 2025 |
| FY2025 | Mar 31, 2023 | $28.96M | Jun 30, 2025 |
| FY2024 | Mar 31, 2022 | $25.22M | Jul 1, 2024 |
| FY2023 | Mar 31, 2021 | $16.15M | Jun 29, 2023 |
| FY2022 | Mar 31, 2020 | $10.66M | Jun 29, 2022 |
| FY2020 | Mar 31, 2019 | ($2.51M) | Jun 29, 2020 |
| FY2020 | Mar 31, 2018 | $4.57M | Jun 29, 2020 |
| FY2019 | Mar 31, 2017 | $25.66M | Jun 21, 2019 |
| FY2018 | Mar 31, 2016 | ($33.12M) | Jun 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($120.70M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | ($116.39M) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | ($136.50M) | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | ($140.06M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($148.96M) | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($154.05M) | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | ($151.81M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($142.53M) | Jun 21, 2019 |
| FY2018 | Mar 31, 2017 | ($138.85M) | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | ($142.66M) | Jun 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $7.11M | Jul 1, 2024 |
| FY2024 | Mar 31, 2023 | $7.83M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $8.54M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $3.19M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $1.13M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | $2.28M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $7.18M | Jun 21, 2019 |
| FY2018 | Mar 31, 2017 | $10.59M | Jun 14, 2018 |
| FY2018 | Mar 31, 2016 | $11.51M | Jun 14, 2018 |
| FY2018 | Mar 31, 2015 | $7.46M | Jun 14, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Mar 31, 2022 | $1.36M | Jun 29, 2022 |
| FY2021 | Mar 31, 2021 | $1.47M | Jun 14, 2021 |
| FY2020 | Mar 31, 2020 | $1.58M | Jun 29, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Jun 29, 2020 |
| FY2018 | Mar 31, 2018 | 0 | Jun 14, 2018 |
| FY2018 | Dec 31, 2017 | 0 | Jun 14, 2018 |
| FY2018 | Sep 30, 2017 | 0 | Jun 14, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Jun 29, 2020 |
| FY2018 | Mar 31, 2018 | 0 | Jun 14, 2018 |
| FY2018 | Dec 31, 2017 | 0 | Jun 14, 2018 |
| FY2018 | Sep 30, 2017 | 0 | Jun 14, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 1.07B | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | 1.07B | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | 1.01B | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | 1.01B | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 1.01B | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | 840.40M | Jun 14, 2021 |
| FY2020 | Mar 31, 2019 | 824.85M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | 802.53M | Jun 21, 2019 |
| FY2018 | Mar 31, 2017 | 927.93M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | 711.44M | Jun 14, 2017 |